Showing results (211-220 of 831) with videos related to

Sort By:
Pageof 84
Leukemia Research|July 29, 2008
The physician-patient relationship and quality of life: lessons from chronic lymphocytic leukemiaTait D Shanafelt, Deborah A Bowen, Chaya Venkat, et al.
Iscience|January 18, 2021
Chronic lymphocytic leukemia B-cell-derived TNFα impairs bone marrow myelopoiesisBryce A Manso, Jordan E Krull, Kimberly A Gwin, et al.
Blood|September 27, 2008
Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitorsElias Jabbour, Hagop M Kantarjian, Dan Jones, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 16, 2013
The achievement of a 3-month complete cytogenetic response to second-generation tyrosine kinase inhibitors predicts survival in patients with chronic phase chronic myeloid leukemia after imatinib failureElias Jabbour, Hagop Kantarjian, Hady Ghanem, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 22, 2015
Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignanciesTalha Badar, Jorge E Cortes, Farhad Ravandi, et al.
Cancer|December 20, 2002
Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemiaMarco Montillo, Alessandra Tedeschi, Susan O'Brien, et al.
Blood|May 22, 2008
Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemiaConstantine S Tam, Hagop Kantarjian, Guillermo Garcia-Manero, et al.
Blood|October 1, 2005
Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylateElias Jabbour, Hagop Kantarjian, Susan O'Brien, et al.
Leukemia Research|October 19, 2006
T-cell large granular lymphocytic (T-LGL) leukemia: experience in a single institution over 8 yearsAhmed Aribi, Yang Huh, Michael Keating, et al.
Blood|March 21, 2012
EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experienceElias Jabbour, Jorge Cortes, Aziz Nazha, et al.
Pageof 84